Scpharmaceuticals INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
SCPHARMACEUTICALS Inc. reported significant revenue growth for FUROSCIX in Q2 2025, driven by increased demand and expanded indications, despite continued operating losses.
scPharmaceuticals Inc. announces increased product revenue and the approval of FUROSCIX for treating edema in patients with chronic kidney disease in its Q1 2025 report.
10-Q/A: scPharmaceuticals Inc. Files Amended Quarterly Report Detailing Insider Trading Arrangements
scPharmaceuticals Inc. has filed an amendment to its quarterly report to disclose Rule 10b5-1 trading arrangements established by its CEO and CFO for tax withholding obligations related to vested stock units.
scPharmaceuticals Inc. reports a significant increase in product revenue for Q3 2024, alongside strategic financial moves and progress in its product pipeline.
scPharmaceuticals Inc. announced its second quarter 2024 financial results, highlighted by a significant increase in product revenue, a new $75 million term loan facility, a $50 million revenue participation agreement, and FDA approval to expand the FUROSCIX label to include NYHA Class IV heart failure patients.
10-Q: scPharmaceuticals Inc. Reports First Quarter 2024 Results, Revenue Growth Driven by FUROSCIX Sales
scPharmaceuticals Inc. saw a significant increase in product revenue in the first quarter of 2024, driven by increased sales of its FUROSCIX product, despite ongoing operating losses.